PubMed ID:
25399731
Public Release Type:
Journal
Publication Year: 2014
Affiliation: From the Mayo Clinic College of Medicine, Rochester, MN (V.E.T., M.C.H., P.C.H.); University of Pittsburgh School of Medicine, Pittsburgh (K.Z.A., C.G.M.); Emory University School of Medicine, Atlanta (A.B.C., F.F.R.-O.); University of Colorado Health Sciences Center, Denver (R.W.S., G.B.); Cleveland Clinic, Cleveland (W.E.B.); Beth Israel Deaconess Medical Center (T.I.S., P.G.C.) and Tufts Medical Center (D.C.M., R.D.P.) - both in Boston; Kansas University Medical Center, Kansas City (F.T.W., J.J.G.) and the National Institutes of Health, Bethesda, MD (M.F.F.).
DOI:
https://doi.org/10.1056/NEJMoa1402686
Authors:
Greene T,
Perrone RD,
Perrone R,
Torres VE,
Abebe KZ,
Abebe KZ,
Bae K,
Bost JE,
Braun W,
Braun WE,
Briggs J,
Brosnahan G,
Brosnahan G,
Chapman A,
Chapman AB,
Czarnecki P,
Czarnecki PG,
El-Zoghby Z,
Flessner M,
Flessner MF,
Gitomer B,
Glockner J,
Grantham J,
Grantham JJ,
Halin N,
HALT-PKD Trial Investigators,
Harris P,
Harris PC,
Henrich W,
Hogan MC,
Hogan MC,
Kelleher C,
King B Jr,
Leonard M,
Martin D,
Masoumi A,
McCullough P,
Meyers CM,
Miller J,
Miskulin D,
Miskulin DC,
Mittal P,
Moe S,
Moore CG,
Moore CG,
Nurko S,
Patel N,
Pedrosa I,
Rahbari-Oskoui F,
Rahbari-Oskoui FF,
Remer E,
Rocco M,
Schrier R,
Schrier RW,
Shayman J,
Star R,
Steinman T,
Steinman TI,
Thompson PA,
Torres V,
Wang C,
Wei J,
Wendler D,
Wetzel L,
Winklhofer F,
Winklhofer FT,
Yu A
Hypertension develops early in patients with autosomal dominant polycystic kidney disease (ADPKD) and is associated with disease progression. The renin-angiotensin-aldosterone system (RAAS) is implicated in the pathogenesis of hypertension in patients with ADPKD. Dual blockade of the RAAS may circumvent compensatory mechanisms that limit the efficacy of monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB).